Seer ROA 2020-2022 | SEER

Current and historical return on assets (ROA) values for Seer (SEER) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Seer ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-03-31 $-0.08B $0.53B -14.83%
2021-12-31 $-0.07B $0.54B -13.21%
2021-09-30 $-0.06B $0.53B -12.47%
2021-06-30 $-0.05B $0.54B -14.16%
2021-03-31 $-0.04B $0.55B -17.41%
2020-12-31 $-0.03B $0.44B -28.96%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.559B $0.007B
Seer Inc. is a life sciences company. It engages in developing Proteograph(TM), which is an integrated solution consisting of consumables, automation instrumentation and proprietary software. Seer Inc. is based in REDWOOD CITY, Calif.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.938B 9.97
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.718B 16.92
Biohaven Pharmaceutical Holding (BHVN) United States $10.276B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.817B 46.07
Emergent Biosolutions (EBS) United States $1.560B 6.68
Myovant Sciences (MYOV) United Kingdom $1.185B 0.00
Zymeworks (ZYME) Canada $0.306B 0.00
Gelesis Holdings (GLS) United States $0.112B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00